» Articles » PMID: 14756433

Prognostic Value of Intratumoral CD8+ T Lymphocyte in Extrahepatic Bile Duct Carcinoma As Essential Immune Response

Overview
Journal J Surg Oncol
Date 2004 Feb 6
PMID 14756433
Citations 48
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Objectives: Tumor-infiltrating lymphocytes form an important aspect of the host defense against an expanding neoplasm. CD8+ T cells have been identified as a prognostic factor in several cancers. Here, we investigate that the influence of CD8+ T cells on extrahepatic bile duct carcinoma (EBDC) patient survival.

Methods: CD8+ T cell immunoreactivity in 58 surgically resected EBDC specimens was investigated. The relationship between CD8+ T cell immunoreactivity and clinical and histopathologic features was analyzed.

Results: Thirty-two tumors (55%) possessed intratumoral CD8+ T cells. The degree of intratumoral CD8+ T cell immunoreactivity demonstrated a significant relationship to lower numbers of lymph node metastasis, reduced venous invasion, decreased perineural invasion, and better pTNM staging. Intratumoral CD8- T cells were also associated with increased patient survival. Multivariate analysis indicated that the presence of intratumoral CD8+ T cells was an independent prognostic factors.

Conclusions: The infiltration of a cancer cell nest by CD8+ T cells is a reliable marker predicting increased survival of patients with EBDC.

Citing Articles

Multi-Omics Profiling Unveils the Complexity and Dynamics of Immune Infiltrates in Intrahepatic Cholangiocarcinoma.

Li X, Wang Y, Guan R, Sheng N, Zhang S Biology (Basel). 2024; 13(10).

PMID: 39452125 PMC: 11504529. DOI: 10.3390/biology13100816.


Clinical prognosticators and targets in the immune microenvironment of intrahepatic cholangiocarcinoma.

Lozzi I, Arnold A, Barone M, Johnson J, Sinn B, Eschrich J Oncoimmunology. 2024; 13(1):2406052.

PMID: 39359389 PMC: 11445892. DOI: 10.1080/2162402X.2024.2406052.


Causal relationship between immune cell phenotypes and risk of biliary tract cancer: evidence from Mendelian randomization analysis.

Hu Y, Wang K, Chen Y, Jin Y, Guo Q, Tang H Front Immunol. 2024; 15:1430551.

PMID: 39050844 PMC: 11266158. DOI: 10.3389/fimmu.2024.1430551.


High immune cell infiltration predicts improved survival in cholangiocarcinoma.

Wirta E, Szeto S, Koppatz H, Nordin A, Makisalo H, Arola J Front Oncol. 2024; 14:1333926.

PMID: 38751812 PMC: 11094285. DOI: 10.3389/fonc.2024.1333926.


Circulating Immune Cells Predict Prognosis and Clinical Response to Chemotherapy in Cholangiocarcinoma.

Shi H, Li Z, Zhu M Curr Med Chem. 2024; 32(3):595-607.

PMID: 38698750 DOI: 10.2174/0109298673296618240424095548.